Selegiline (Figure 5), another MAO-B inhibitor with antioxidant properties, was also evaluated in a double-blind, placebo-controlled trial for treatment of ALS, but no significant effect was observed on the clinical progression of ALS [72]. This evidence concerns the gene MAOB and amyotrophic lateral sclerosis.